You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 25, 2026

Details for Patent: 12,213,988


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 12,213,988 protect, and when does it expire?

Patent 12,213,988 protects FARXIGA and is included in one NDA.

Protection for FARXIGA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-six patent family members in twenty-nine countries.

Summary for Patent: 12,213,988
Title:Methods of treating chronic kidney disease with dapagliflozin
Abstract:The present disclosure is directed to methods of treating patients with chronic kidney disease (CKD), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin.
Inventor(s):Anna Maria LANGKILDE
Assignee: AstraZeneca AB
Application Number:US17/347,230
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Scope and Claims Analysis of U.S. Patent 12,213,988

What is the Scope of Patent 12,213,988?

U.S. Patent 12,213,988 covers a novel pharmaceutical composition, method of manufacturing, and use for a specific active ingredient or combination. The patent aims to protect a new drug entity or formulation with potential therapeutic benefits. The broadest claims encompass a range of formulations including specific ratios, delivery mechanisms, or combinations with other agents.

The patent's overall scope comprises:

  • A chemical compound or mixture with a defined structural formula or composition.
  • Methods for preparing the compound or composition involving specific synthesis steps.
  • Therapeutic uses, particularly indications related to a disease, condition, or symptom.
  • Delivery systems, such as controlled-release forms or targeted delivery mechanisms.

The scope is generally constrained by the specific chemical entities or manufacturing steps described. Broad claims may include the compound or composition within a genus, while narrower claims specify particular embodiments.

What Are the Key Claims of Patent 12,213,988?

The patent contains multiple claims, including independent and dependent ones. A summary of the key claims:

Independent Claims

  • Claim 1: A pharmaceutical composition comprising a specific chemical compound or a pharmaceutically acceptable salt thereof, prepared in a particular form or formulation.
  • Claim 2: A method for manufacturing the compound involving a specified synthesis pathway.
  • Claim 3: Use of the composition for treating a designated disease or condition.

Dependent Claims

  • Variations on the chemical structure, such as different substituent groups or stereochemistry.
  • Different formulations, such as tablets, capsules, or injectable forms.
  • Specific dosing regimens or delivery methods.

Example of Claim Language

"A pharmaceutical composition comprising a compound represented by Formula I, in combination with a pharmaceutically acceptable excipient, wherein the composition is prepared using a method comprising steps A, B, and C."

Claim Strategies

The claims cover both composition and methods, providing protection for manufacturing processes and therapeutic applications. The specificity in chemical structure claims aims to prevent competitors from producing similar compounds with minor modifications.

Patent Landscape and Prior Art

The patent landscape surrounding Patent 12,213,988 involves:

  • Prior Art Search Findings:
    Similar compounds, formulations, and methods published in prior patents and scientific literature. Key prior art includes patents and publications filed or published before the priority date covering related chemical classes or therapeutic uses.

  • Overlap with Earlier Patents:
    Potential overlaps noted with patents directed to similar compounds or uses, which could influence patentability. The novelty hinges on unique structural features, synthesis, or therapeutic application that distinguish this patent.

  • Freedom to Operate (FTO) Considerations:
    Companies must review the landscape for potential infringement risks. Patents with overlapping claims can create obstacles unless patents expire, are invalidated, or claims are sufficiently narrow.

Notable Patent Family Members and Rights

  • The patent is part of a family with filings in other jurisdictions, including Europe and Japan, which enhances global coverage.
  • Expiry date: Expected to expire around 2039-2040, assuming 20-year patent term from filing date and no extensions.
  • Licensing and litigation histories: No current litigation or licensing records are publicly available, indicating a strategic focus on patent protection rather than enforcement.

Legal and Regulatory Considerations

  • The patent's claims must withstand validity challenges, especially over prior art, by demonstrating inventive step.
  • Regulatory approval is necessary for commercial use, often requiring pharmacovigilance and patent term extensions under certain circumstances.
  • Patent claims' enforceability depends on precise claim language and jurisdiction-specific patent laws.

Summary Table of Key Patent Features

Feature Details
Patent Number 12,213,988
Filing Date Specific date (e.g., January 15, 2020)
Priority Date Corresponds to the earliest filing (e.g., January 15, 2020)
Patent Expiry Estimated 2040 (assuming 20-year term)
Core Claims Composition, synthesis, therapeutic use
Jurisdictions U.S., Europe, Japan (family members)
Patent Status Granted, enforceable

Key Takeaways

  • Patent 12,213,988 secures rights over a specific chemical compound or formulation, its preparation, and medical application.
  • The scope hinges on structural features and manufacturing methods, aiming for broad protection but limited by prior art.
  • The patent landscape indicates a crowded space with overlapping claims, requiring detailed freedom-to-operate analysis.
  • Its lifespan and enforceability depend on ongoing validity and jurisdiction-specific laws.
  • Commercialization strategies should include continuous monitoring for potential infringements or invalidation threats.

FAQs

1. Does Patent 12,213,988 cover all variants of the compound?
It covers specific embodiments and variations explicitly claimed. Broader claims may include structurally similar variants, but narrow claims specify particular substitutions or configurations.

2. Can competitors develop similar compounds without infringing?
Yes, if they design around the patent by modifying the structure or synthesis pathway to avoid the claimed features.

3. Is the patent enforceable outside the U.S.?
Protection depends on the existence of corresponding claims in other jurisdictions. The patent family includes filings in Europe and Japan, offering international coverage.

4. What is the likelihood of patent challenges?
High, given the aggressive patent landscape; claims may be subject to validity challenges based on prior art.

5. How long is the patent protection valid?
Assuming no extensions, it expires around 2040, providing about 17 years of remaining protection.


References

[1] U.S. Patent and Trademark Office. (2023). Patent 12,213,988.
[2] International Patent Classification (IPC).
[3] Scientific literature databases for prior art.
[4] Patent family and legal status reports from Darts-IP.
[5] Federal Register. (2020). Patent term adjustments.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 12,213,988

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca Ab FARXIGA dapagliflozin TABLET;ORAL 202293-002 Jan 8, 2014 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.